Cargando…
Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update
Physicians treating patients affected by nonmuscle-invasive bladder cancer (NMIBC) have been in shock during the last six years since manufacturing restrictions on the production of the first-option medicine, Mycobacterium bovis Bacillus Calmette-Guérin (BCG), have resulted in worldwide shortages. T...
Autores principales: | Guallar-Garrido, Sandra, Julián, Esther |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025668/ https://www.ncbi.nlm.nih.gov/pubmed/32104666 http://dx.doi.org/10.2147/ITT.S202006 |
Ejemplares similares
-
Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer
Publicado: (2021) -
Bacillus Calmette-Guerin (BCG): the adroit vaccine
por: Adesanya, Oluwafolajimi A., et al.
Publicado: (2021) -
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007) -
VARIABILITY OF BCG STRAINS (BACILLUS CALMETTE-GUÉRIN)
por: Suter, W. Emanuel, et al.
Publicado: (1951) -
Bacillus Calmette-Guerin (BCG) vaccine in Iran
por: Fallah, Fatemeh, et al.
Publicado: (2018)